ACOG Updates Menopause Guidelines to Expand Hormone Therapy Options

According to CBS News, the American College of Obstetricians and Gynecologists (ACOG) has updated its guidance on treating menopause and perimenopause symptoms, strengthening support for hormone therapy for many people with hot flashes and night sweats. The change matters because it puts symptom relief back at the center of a decision that depends on an individual’s health history, eligibility and timing.

What the guidance changes

CBS reports that this is ACOG’s first change to its advice on menopause hormone therapy in more than a decade. The guidance supports hormone therapy for vasomotor symptoms, including hot flashes and night sweats. Sleep problems are also discussed in the report.

The treatment can be given in several forms, including pills, patches, sprays, gels and a vaginal ring. Some people may benefit from low-dose vaginal estrogen. These options are not interchangeable by default: the appropriate treatment depends on the symptoms and the patient’s clinical circumstances.

The report describes falling estrogen and progesterone levels as part of the menopause transition and links those changes with symptoms such as hot flashes and night sweats. It also notes that lower hormone levels can affect bone density. That background does not establish that hormone therapy is suitable for every symptom or every patient.

Eligibility remains the key constraint

A stronger recommendation is not a blanket clearance. According to CBS News, ACOG advises against hormone therapy for people with a history of blood clots, stroke or liver disease, and for those with a personal history of breast cancer. Anyone considering treatment should discuss their own medical history with a healthcare professional rather than infer eligibility from the guideline’s general direction.

The report says ACOG recommends starting therapy before age 60 or within 10 years of menopause onset. It also describes newer research as suggesting that age and dosing can affect safety. That is not a guarantee of safety for an individual, and the available reporting does not provide enough detail to assess a specific regimen or quantify its risks.

What to discuss at an appointment

A useful consultation should establish which symptoms need treatment, whether hormone therapy is appropriate given the patient’s history, and which delivery method is being considered. For people who are not eligible for hormone therapy, the CBS report says nonhormonal options may be available; a menopause-trained specialist can help review them.

The evidence-based takeaway is narrow: ACOG’s reported guidance gives hormone therapy stronger support for common symptoms, but it does not remove the need for individualized screening. The treatment decision still turns on eligibility, timing and clinical assessment.